RAD RADIOPHARM THERANOSTICS Year Ended 30 June 2026 Annual Report: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F(Mark One)? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR? ANNUAL REPORT PURSUANT TO SECTION 13...
Annual Report and Form 20-F
Filed with ASX · · 182 pages · English
Release
Radiopharm Theranostics Limited on 6ix
Story so far
Earlier from Radiopharm Theranostics
- Change of Director's Interest Notices x 4
- Notification regarding unquoted securities - RAD
- RADOC New Class Options Range of Units and Top 20 Holders
- Application for quotation of securities - RAD
- Share purchase plan completed
Later from Radiopharm Theranostics
- Appendix 4G and Corporate Governance Statement
- Change of Director's Interest Notice (RC)
- Notification of cessation of securities - RAD
- RAD Completes Meeting with US FDA for Development of RAD101
- Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics